WO2021005941A1 - Composition contenant un extrait d'albizia julibrissin - Google Patents

Composition contenant un extrait d'albizia julibrissin Download PDF

Info

Publication number
WO2021005941A1
WO2021005941A1 PCT/JP2020/022683 JP2020022683W WO2021005941A1 WO 2021005941 A1 WO2021005941 A1 WO 2021005941A1 JP 2020022683 W JP2020022683 W JP 2020022683W WO 2021005941 A1 WO2021005941 A1 WO 2021005941A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
albizia
gene
composition
skin
Prior art date
Application number
PCT/JP2020/022683
Other languages
English (en)
Japanese (ja)
Inventor
知宏 菅原
周平 山本
周子 山下
Original Assignee
東洋紡株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 東洋紡株式会社 filed Critical 東洋紡株式会社
Priority to CN202080035514.4A priority Critical patent/CN113825493A/zh
Priority to JP2021530534A priority patent/JPWO2021005941A1/ja
Publication of WO2021005941A1 publication Critical patent/WO2021005941A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives

Definitions

  • the present invention suppresses or prevents an abnormality in the expression rhythm of a clock gene in skin cells showing an expression rhythm of the clock gene in an irregular or abnormal state as compared with the expression rhythm of a normal clock gene.
  • the present invention relates to a composition containing a nemunoki extract.
  • the present invention also relates to an anti-inflammatory agent containing a silk tree bark extract as an active ingredient. More specifically, the present invention relates to a composition for external use on the skin, which has an effect of suppressing erythema after irradiation with ultraviolet rays by using the anti-inflammatory agent.
  • the present invention relates to an anti-glycation agent utilizing the anti-glycation effect of Albizia bark extract.
  • the present invention relates to an anti-glycation agent having an effect of suppressing the production of a glycation product produced by the reaction of a protein and a sugar, and an external composition for skin containing the anti-glycation agent.
  • rhythm Especially in mammals, the center of function of circadian rhythm is the suprachiasmatic nucleus located in the hypothalamus in the brain. By transmitting periodic signals from the suprachiasmatic nucleus to the peripheral tissues via nerve transmission and hormones, various physiological functions of the whole body are regularly tuned at regular intervals.
  • rhythm is regulated at the transcriptional level by the interaction of multiple clock genes.
  • Bmal1 and Lockk form a heterodimer, which binds to the E-box sequence on DNA to clock genes such as Per and cry, as well as non-clock genes such as many hormones, cytokines or enzymes. Regulates the expression of the group.
  • the translated Per and Cry proteins form Per / Cry heterodimers and translocate into the nucleus, suppressing transcriptional activity by Bmal1 / Lock.
  • Non-Patent Document 1 Skin cells are no exception, and it has been suggested that aquaporins are regulated by BMAL1 / CLOCK in terms of barrier function. In addition, there is a report suggesting that there is a close relationship between active oxygen production and BMAL1 (Non-Patent Document 1). On the other hand, it has been reported that when oxidative stress is applied to cultured skin cells, the expression rhythm of clock genes becomes abnormal, and it is difficult to imagine that the abnormal expression rhythm of clock genes in these skin cells causes dysfunction of physiological functions. Absent.
  • Patent Document 1 reports a clock gene expression regulator containing a sphingoid base as an active ingredient.
  • the disturbance of the clock gene is induced under the stress of hydrogen peroxide, and attention is paid to the recovery of the amplitude.
  • Patent Document 2 reports a circadian rhythm improving agent containing a passionflower extract (excluding those containing harumine).
  • attention is paid to the enhancement of the expression (amplitude) of the clock gene under non-stress.
  • Patent Document 3 reports a composition for promoting clock gene expression, which contains black ginger (Kaempferia parviflora). The present invention also focuses on the enhancement of the expression (amplitude) of the clock gene under non-stress.
  • Patent Document 4 by adding the water extract of Nemunoki bark to mouse embryonic fibroblasts, the course of its amplitude in the expression rhythm of the clock gene (Per2 gene) of the cells. It was found that the target attenuation can be suppressed. Furthermore, it has been shown that the extract can advance or decrease the phase of the expression rhythm of the Per2 gene in a concentration-dependent manner depending on the timing of administration to cells, and is flexible to the clock gene. Action has been suggested.
  • Albizia is a deciduous tree of the leguminous family that grows naturally in sunny wetlands such as forest edges and wilderness in the mountains south of the Tohoku region in Japan. It is also distributed and cultivated overseas in China, Southeast Asia, etc. To.
  • the bark is collected around the flowering season, washed with water, dried in the sun and chopped to an appropriate length, and is called arthralgia. In the private sector, it is taken with the expectation of arthritis, low back pain, diuresis, edema, and tonicity. For external use, it has been used as a cold compress for swelling, bruising wounds, and joint pain with a decoction, or as a bath water. It is known that the bark contains triterpene saponins (many julibrosides), flavonoids (geraldone, isoocanin, luteolin, etc.), tannins, and the like. (Non-Patent Document 2)
  • UVA ultraviolet rays that reach the surface of the earth
  • UVB UVB
  • UVA ultraviolet rays that reach from the sun
  • sunburn inflammation reaction due to sunburn
  • suntan that makes the skin black after a few days (suntan) It has the effect of causing a pigmentation reaction
  • UVB having a short wavelength is known not only to cause inflammation and spots, but also to have a strong effect on living organisms such as damaging epidermal cells and DNA on the skin surface.
  • Patent Document 5 reports a skin external preparation containing a plant selected from Coltsfoot (Tussilago farfara L.) and Inchinko (Artemisia capillan's Thunberg) or an extract thereof.
  • Patent Document 6 reports an external preparation for skin containing ascorbic acid and a derivative thereof or a salt thereof, glycyrrhizic acid and a derivative thereof or a salt thereof, a component derived from rice bran, and a gentiana extract.
  • Patent Document 7 reports an external preparation for skin containing an apple extract.
  • the amino group of the protein and the carbonyl group of the reducing sugar are non-enzymatically bonded to form an advanced glycation end product.
  • This reaction is called the Maillard reaction or saccharification reaction.
  • the binding reaction between this protein and the reducing sugar also occurs in the living body, and the glycated protein is always formed.
  • AGEs advanced glycation end-products
  • AGEs are produced not only from glucose but also from various sugars such as autoxidation and decomposition products of glucose.
  • pentosidine, crosulin, carboxymethyl lysine, pyrazine and the like are known.
  • Patent Document 8 describes an AGEs production inhibitory action containing a budreja axilaris leaf extract as an active ingredient.
  • Patent Document 9 describes an anti-glycation agent for a protein containing propolis or a processed product thereof as an active ingredient.
  • Patent Document 10 describes an anti-glycation cosmetic containing plum vinegar.
  • new anti-glycation agents are available from the viewpoints of diversification of formulations, expansion of options for formulation, synergistic effects using anti-glycation agents with different mechanisms, and safer and more effective anti-glycation effects. Development of a saccharifying agent is required.
  • JP-A-2018-138524 Japanese Unexamined Patent Publication No. 2018-43970 Japanese Unexamined Patent Publication No. 2016-21703 Japanese Unexamined Patent Publication No. 2018-0587883 Japanese Unexamined Patent Publication No. 8-175598 JP-A-2010-47535 Japanese Unexamined Patent Publication No. 2013-095704 Japanese Unexamined Patent Publication No. 2011-102270 Japanese Unexamined Patent Publication No. 2012-077042 Japanese Unexamined Patent Publication No. 2012-214434
  • an object of the present invention to find a material that suppresses or prevents disturbance of the expression rhythm of a clock gene. As a result, it is an object to prevent various diseases and symptoms caused by the disorder of the expression rhythm of the clock gene. Another object of the present invention is to find an anti-inflammatory agent that suppresses erythema induced by ultraviolet rays. Furthermore, an object of the present invention is to provide an anti-glycation agent having an action of suppressing the production of a glycation product generated by a reaction between a protein and a sugar.
  • the present inventors have an effect that the erythema extract effectively suppresses or prevents the disturbance of the expression rhythm of the clock gene caused by oxidative stress, and that the disturbance of the expression rhythm is caused by ultraviolet rays.
  • the nemnoki bark extract has an anti-inflammatory effect that suppresses the erythema, and for the production of glycation products produced by the reaction of protein and sugar, the nemnoki bark extract is glycated. We have found that it has an anti-glycation effect that suppresses the reaction, and have completed the present invention.
  • Item 1 A nemunoki extract-containing composition used for skin cells exhibiting an irregular or abnormal clock gene expression rhythm as compared to a normal clock gene expression rhythm.
  • Item 2. Item 2.
  • Item 3. The expression rhythm of the irregular or abnormal clock gene is caused by any factor selected from the group consisting of oxidative stress, ultraviolet rays, external stimuli by drugs, physiological stress, and internal factors due to aging.
  • Item 3. The nemunoki extract-containing composition according to Item 1 or 2.
  • Item 4. Item 3.
  • Item 5. Item 4. The composition containing Albizia japonica extract according to any one of Items 1 to 4, wherein the skin cells are human epidermal keratinocytes.
  • Item 6. Item 4. The composition containing Albizia japonica extract according to any one of Items 1 to 5, wherein the clock gene is a gene showing diurnal periodicity in the expression rhythm.
  • Item 8. Item 2. The Albizia extract-containing composition according to Item 7, wherein the clock gene is the Bmal1 gene.
  • Item 9. Item 8. The composition containing Albizia japonica extract according to any one of Items 1 to 8, wherein the Albizia japonica extract is an Albizia bark extract.
  • Item 10. Item 2. The composition containing Albizia japonica extract according to any one of Items 1 to 9, wherein the Albizia japonica extract is 0.001 to 10% by mass of the total composition applied to the skin cells.
  • Item 11. Item 2. The Albizia extract-containing composition according to Item 10, wherein the Albizia extract is 0.005 to 1% by mass of the total composition applied to the skin cells.
  • a cosmetic comprising the composition containing the Albizia japonica extract according to any one of Items 1 to 11.
  • Item 13 An external preparation for skin containing the composition containing the Albizia japonica extract according to any one of Items 1 to 11.
  • Item 14. Item 3. The external preparation for skin according to Item 13, wherein the Albizia japonica extract contains 0.00001 to 5.0% by weight in dry weight.
  • Item 15. An anti-inflammatory agent containing a silk tree bark extract extracted from the bark of Albizia japonica with water.
  • Item 17. Item 5.
  • the anti-inflammatory agent according to Item 15 or 16 which has an action of suppressing erythema of the skin induced by ultraviolet irradiation.
  • Item 18. Item 2. The anti-inflammatory agent according to any one of Items 15 to 17, wherein the Albizia bark extract is in the concentration range of 0.00001 to 5.0% by weight by dry weight.
  • Item 19. Item 8. The anti-inflammatory agent according to Item 18, wherein the Albizia bark extract is in a concentration range of 0.00005 to 3.0% by weight by dry weight.
  • Item 26 Item 25. The anti-glycation agent according to Item 25, wherein the Albizia bark extract is contained in a concentration range of 0.00005 to 3.0% by weight by dry weight.
  • Item 27 Item 25. The anti-glycation agent according to Item 25, wherein the Albizia bark extract is contained in a concentration range of 0.0001 to 1.0% by mass by dry weight.
  • Item 28 An external composition for skin containing the anti-glycation agent according to any one of Items 22 to 27.
  • the Albizia japonica extract of the present invention it can be expected to suppress or prevent the disturbance of the clock gene caused by oxidative stress and the like, and it is possible to provide an external preparation for skin for the purpose of the effect.
  • the Nemunoki bark extract it is possible to provide an anti-inflammatory agent that suppresses erythema of the skin induced by ultraviolet rays, and to suppress the production of glycation products caused by the reaction between protein and sugar. Expected, an external composition for skin can be provided for these effects.
  • Example 1 It is a figure which shows the result of having evaluated the suppression or preventive action against the disturbance of the expression rhythm of the target clock gene in the human normal neonatal epidermal keratinocyte in Example 1 (hydrogen peroxide-free group / silk tree extract-free addition). Ward).
  • Example 1 it is a figure which shows the result of having evaluated the suppression or preventive action against the disturbance of the expression rhythm of the target clock gene in the human normal neonatal epidermal keratinocyte (hydrogen peroxide addition group / silk tree extract non-addition group). ).
  • the present invention is characterized in that it suppresses or prevents an abnormality in the expression rhythm of a clock gene in skin cells showing an irregular or abnormal expression rhythm of the clock gene as compared with the expression rhythm of a normal clock gene.
  • a composition containing a nemunoki extract is provided.
  • the skin cells to be applied include human epidermal keratinocytes, human skin fibroblasts, human epidermal melanocytes, human skin microvascular endothelial cells, human skin microlymphocyte endothelial cells, human dermal papilla cells and the like. In particular, it is preferably used for human epidermal keratinocytes.
  • the bark is mainly used as the part of the plant body in the extract, but the whole can be used without specifying this. Needless to say, it is not limited to the examples described below.
  • the silk tree extract refers to the plant itself of the silk tree genus plant, its cut product, dried powder, and its extract.
  • the "extract” includes both a state containing the extraction solvent and a state in which the extraction solvent is removed, and also includes a state in which the extract is further purified after the removal of the extraction solvent.
  • the Nemunoki extract is extracted from a plant of the genus Nemunoki, typically its branches and leaves, and is crushed raw or dried, and then water as an extraction solvent, preferably heat at 70 to 100 ° C. It is obtained by performing extraction with water or an organic solvent. If necessary, the extraction can be performed by combining water extraction and organic solvent extraction, but considering the effect when applied to a living body, it is preferable to perform extraction only by water extraction.
  • water for example, water; alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; tetrahydrofuran and diethyl ether Chain and cyclic ethers such as; polyethers such as polyethylene glycol; hydrocarbons such as hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as benzene and toluene; pyridines; fats and oils, waxes and other oils Of these, water, alcohols, and a water-alcohol mixed solution are preferable, and hot water is particularly preferable to be used as an extraction solvent.
  • alcohols such as methanol, ethanol, propanol and butanol
  • polyhydric alcohols such as propylene glycol and butylene glyco
  • the crushed plant of the genus Silkus is extracted under heating and reflux.
  • the extraction conditions differ depending on the solvent used. For example, when extracting with water, 1 to 100 parts by weight of water is used for 1 part by weight of Nemunoki, and the temperature is 4 to 100 ° C. for 10 minutes to 7 days. It is preferable to extract by using 5 to 20 parts by weight of water with respect to 1 part by weight of the bark of Nemunoki, and it is more preferable to extract at a temperature of 70 to 100 ° C. over 30 minutes to 2 hours. Further, from the viewpoint of further improving the extraction efficiency, pressurization, stirring, ultrasonic treatment and the like may be performed at the same time as the extraction treatment. Further, after such an extraction treatment, it may be separated from the residue by filtration or centrifugation.
  • the Nemunoki extract is usually given a tar-like black-brown extract by distilling off the extraction solvent under reduced pressure, and an excipient can be added if necessary.
  • the extraction solvent is non-toxic, for example, water, it can be used for preparation while containing the extraction solvent, but the extract from which the extraction solvent has been separated can also be used for preparation.
  • Extraction solvent The extract after separation can also be redissolved in a suitable solvent, for example, water and used for preparation. Further, the extract thus obtained can be purified or improved in potency by purification means, for example, fractional extraction, partitioning between two solvents, fractional adsorption / elution with an appropriate adsorbent, chromatography or the like. ..
  • the Albizia japonica extract obtained as described above can be used as it is for suppressing or preventing abnormalities in the expression rhythm of the total gene, but it is preferably used by blending it with an external preparation, particularly a skin external preparation.
  • the amount to be blended in the external preparation is determined by the degree of absorption, the degree of action, the product form, the frequency of use, etc., and is not particularly limited, but the concentration is 0.00001 to 5.0% by weight in dry weight.
  • the range is preferably in the range of 0.00005 to 3.0% by weight, and particularly preferably in the range of 0.0001 to 1.0% by weight. If the content of Albizia japonica extract is less than 0.00001% by weight, a sufficient effect is not exhibited, and even if 5.0% by weight or more is added, the effect cannot be expected to be enhanced.
  • the composition containing Albizia japonica extract of the present invention contains Albizia japonica extract as an active ingredient.
  • the action of suppressing the disturbance of the expression rhythm of the clock gene due to oxidative stress or the like includes the action of a physiologically active substance such as a polyphenol compound or a terpenoid compound contained in the nemunoki extract on the clock gene.
  • these actions include an action of suppressing the disturbance of the expression rhythm of the clock gene in the peripheral cells.
  • the inhibitory effect on the expression rhythm of the clock gene can be evaluated by adding the composition of the present invention to cultured cells and quantifying the intracellular gene expression level by real-time PCR.
  • the clock gene may be a gene having a function of controlling the circadian rhythm (biological clock) and is not particularly limited, but for example, a Period gene (Per1, Per2, Per3, etc.), Bmal. Genes (Genes also called Arntl, Mop3, Tic, Jap3, Pasd3, bHLHe5, Bmal1, Bmal2, etc.), Cryptochrome genes (Cry1, Cry2, etc.), Lock gene, Ror gene, Rev-erb gene, E4BP gene, GSK3 ⁇ gene , CK1 gene, Dec gene, but in the present invention, Bmal1 gene is preferable. As a result, it is considered that the action of the clock-controlled gene whose expression is controlled by the clock gene also extends. It has also been reported that 43% of the genes encoding proteins are controlled by clock genes at any part of the body (PNAS, Vol.111, No.45, p16219-16224; 2014). It is also expected to act on the clock-controlled gene of.
  • a Period gene Per1, Per2, Per3,
  • the expression of the clock gene in the present invention is related not only to the expression at the transcription level (expression as mRNA) but also to the expression at the translation level (expression as a protein).
  • “change in clock gene expression” includes an increase or decrease in the expression level of a clock gene and a change in the expression rhythm (at least one of amplitude, phase and cycle length) of the clock gene. Is done.
  • Amplitude is the width from the peak to the trough in the rhythm, that is, the magnitude of vibration.
  • the range of the expression level of the clock gene in the peak-to-peak or trough-to-trough period is shown. It is known that the amplitude of a clock gene is attenuated by a decrease in cell activity, aging, stress, and the like.
  • Phase refers to a specific position in one cycle (for example, peak to peak, trough to trough).
  • cycle length is the length of one cycle.
  • Albizia bark extract can suppress phase retreat and cycle length extension due to oxidative stress, and can maintain a normal clock gene expression rhythm.
  • composition containing Albizia japonica extract of the present invention can suppress abnormalities in the expression rhythm of the clock gene and the circadian rhythm controlled by the expression rhythm, and thus can improve or prevent the symptoms caused by the abnormalities. can do.
  • oxidative stress and the like in the present invention include oxidative stress caused by hydrogen peroxide and oxidative stress generated inside cells by ultraviolet rays (UV-A, UV-B, UV-C).
  • the composition containing Albizia japonica extract of the present invention may contain other raw materials in addition to the Albizia japonica extract as long as the effects of the present invention are not impaired.
  • raw materials include water, excipients, antioxidants, preservatives, wetting agents, thickeners, buffers, adsorbents, solvents, emulsifiers, stabilizers, surfactants, lubricants, etc.
  • examples thereof include water-soluble polymers, sweeteners, flavoring agents, acidulants, alcohols and the like.
  • the antioxidant of the present invention may contain other active ingredients as long as the effects of the present invention are not impaired.
  • the active ingredient include antioxidant components, anti-aging components, anti-inflammatory components, whitening components, cell activating components, vitamins, blood circulation promoting components, moisturizing components, and preventing and / or repairing DNA damage.
  • examples thereof include components having, anti-glycation components, peptides or derivatives thereof, amino acids or derivatives thereof, hydroquinone glycosides and esters thereof.
  • the ratio of the nemnoki extract in the nemnoki extract-containing composition is preferably 0.001 to 10% by mass, more preferably 0.01 to 5% by mass, and particularly preferably 0.1 to 2% by mass.
  • the Albizia bark extract obtained as described above can be used as it is as an anti-inflammatory agent, but it is preferable to use it by blending it with an external composition, particularly a skin external composition.
  • the amount to be blended in the external composition is determined by the degree of absorption, the degree of action, the product form, the frequency of use, etc., and is not particularly limited, but is 0.00001 to 5.0% by weight in dry weight.
  • the concentration range is preferably in the range of 0.00005 to 3.0% by weight, particularly preferably in the range of 0.0001 to 1.0% by weight. If the content of Albizia bark extract is less than 0.00001% by weight, a sufficient effect is not exhibited, and even if 5.0% by weight or more is added, the effect cannot be expected to be enhanced.
  • the external composition for skin containing the Albizia bark extract of the present invention contains the Albizia bark extract as an active ingredient.
  • the anti-inflammatory effect of the Albizia bark extract in the present invention includes the action of physiologically active substances such as polyphenol compounds and terpenoid compounds contained in the Albizia bark extract. More specifically, it is considered that the physiologically active substance suppresses erythema of the skin induced by ultraviolet rays or the like. This erythema-suppressing effect can be evaluated by measuring the skin color after ultraviolet irradiation.
  • the Albizia bark extract obtained as described above can be used as it is as an anti-glycation agent, but it is preferable to use it by blending it with an external composition, particularly a skin external composition.
  • the amount to be blended in the external composition is determined by the degree of absorption, the degree of action, the product form, the frequency of use, etc., and is not particularly limited, but is 0.00001 to 5.0% by weight in dry weight.
  • the concentration range is preferably in the range of 0.00005 to 3.0% by weight, particularly preferably in the range of 0.0001 to 1.0% by weight. If the content of Albizia bark extract is less than 0.00001% by weight, a sufficient effect is not exhibited, and even if 5.0% by weight or more is added, the effect cannot be expected to be enhanced.
  • the external composition for skin containing the Albizia bark extract of the present invention contains the Albizia bark extract as an active ingredient.
  • the anti-glycation effect of the Albizia bark extract in the present invention includes the action of physiologically active substances such as polyphenol compounds and terpenoid compounds contained in the Albizia bark extract. More specifically, the bioactive substances are believed to inhibit the reaction between proteins and sugars. This anti-glycation effect can be evaluated, for example, by quantifying a carbonyl group as an index of a glycation product produced by a reaction between a protein and a sugar.
  • the composition containing the Albizia japonica extract of the present invention includes cosmetics, non-pharmaceutical products, foods and drinks, pharmaceuticals, if necessary, as long as the effects of the present invention are not impaired. It can be blended in combination with the ingredients and additives used in the above.
  • fats and oils avocado oil, almond oil, uikyo oil, sesame oil, olive oil, orange oil, orange rafer oil, sesame oil, cacao fat, chamomile oil, carrot oil, cucumber oil, beef fat, beef fat fatty acid, kukui nut oil, Saflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, persic oil, castor oil, cottonseed oil, peanut oil, turtle oil, mink oil, egg yolk oil, cacao butter, palm oil, palm kernel oil, mokurou, coconut oil , Beef fat, pork fat, hardened oil, hardened coconut oil and the like.
  • waxes examples include beeswax, carnauba wax, whale wax, lanolin, liquid lanolin, reduced lanolin, hard lanolin, candelilla wax, montan wax, cellac wax and the like.
  • mineral oil examples include liquid paraffin, petrolatum, paraffin, ozokelide, selecin, microcrystan wax, polyethylene powder, squalene, squalane, and pristane.
  • fatty acids examples include lauric acid, myristic acid, palmitic acid, stearic acid, bechenic acid, oleic acid, 12-hydroxystearic acid, undecylenic acid, tall oil, natural fatty acids such as lanolin fatty acid, isononanoic acid, caproic acid, 2- Examples thereof include synthetic fatty acids such as ethylbutanoic acid, isopentanoic acid, 2-methylpentanoic acid, 2-ethylcaproic acid and isopanoic acid.
  • alcohols examples include natural alcohols such as ethanol, isopropanol, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, lanolin alcohol, cholesterol and phytosterol, synthetic alcohols such as 2-hexyldecanol, isostearyl alcohol and 2-octyldodecanol, and oxidation.
  • natural alcohols such as ethanol, isopropanol, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, lanolin alcohol, cholesterol and phytosterol
  • synthetic alcohols such as 2-hexyldecanol, isostearyl alcohol and 2-octyldodecanol, and oxidation.
  • Ethylene ethylene glycol, diethylene glycol, triethylene glycol, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, polyethylene glycol, propylene oxide, propylene glycol, polypropylene glycol, 1,3-butylene glycol,
  • polyhydric alcohols such as glycerin, batyl alcohol, pentaerythritol, sorbitol, mannitol, glucose and sucrose.
  • Esters include isopropyl myristate, isopropyl palmitate, butyl stearate, hexyl laurate, myristyl myristate, oleyl oleate, decyl oleate, octyldodecyl myristate, hexyldecyl dimethyloctanoate, cetyl lactate, myristyl lactate, Examples thereof include diethyl phthalate, dibutyl phthalate, lanolin acetate, ethylene glycol monostearate, propylene glycol monostearate, and propylene glycol dioleate.
  • metal number examples include aluminum stearate, magnesium stearate, zinc stearate, calcium stearate, zinc palmitate, magnesium myristate, zinc laurate, zinc undecylene and the like.
  • Gum and water-soluble polymer compounds include arabic rubber, benzoin rubber, dammar rubber, guayaku fat, Irish moss, karaya rubber, tragant rubber, carob rubber, chitin seed, agar, casein, dextrin, gelatin, pectin, starch, carrageenan, and carboxyalkyl.
  • Surfactants include anionic surfactants (carboxylates, sulfonates, sulfates, phosphates), cationic surfactants (amine salts, quaternary ammonium salts), and amphoteric surfactants (carboxylic acids).
  • Type amphoteric surfactant sulfate ester type amphoteric surfactant, sulfonic acid type amphoteric surfactant, phosphoric acid ester type amphoteric surfactant), nonionic surfactant (ether type nonionic surfactant, ether ester type non-surfactant) Ionic surfactants, ester-type nonionic surfactants, block polymer-type nonionic surfactants, nitrogen-containing nonionic surfactants), other surfactants (natural surfactants, derivatives of protein hydrolysates, High-molecular-weight surfactants, surfactants containing titanium / silicon, fluorocarbon-based surfactants) and the like.
  • nonionic surfactant ether type nonionic surfactant, ether ester type non-surfactant
  • Ionic surfactants ester-type nonionic surfactants, block polymer-type nonionic surfactants, nitrogen-containing nonionic surfactants
  • other surfactants natural surfactants, derivatives
  • vitamin A1 As vitamins, retinol, retinal (vitamin A1), dehydroretinal (vitamin A2), carotene, lycopene (provitamin A) in the vitamin A group, thiamine hydrochloride, thiamine sulfate (vitamin B1) in the vitamin B group, Riboflavin (vitamin B2), pyridoxin (vitamin B6), cyanocobalamine (vitamin B12), folic acid, nicotinic acid, pantothenic acid, biotin, choline, inositol, ascorbic acid and its derivatives in the vitamin C group, ascorbic acid and its derivatives in the vitamin D group , Ergocalciferol (vitamin D2), cholecalciferol (vitamin D3), dihydrotaxterol, tocopherol and its derivatives in the vitamin E group, ubiquinones, phytonadion (vitamin K1), menaquinone (vitamin K2) in the
  • Amino acids include valine, leucine, isoleucine, threonine, methionine, phenylalanine, tryptophan, lysine, glycine, alanine, asparagine, glutamine, serine, cysteine, cystine, tyrosine, proline, hydroxyproline, aspartic acid, glutamic acid, hydroxylysine, arginine. , Ornitine, histidine and the like, their sulfates, phosphates, nitrates, citrates, amino acid derivatives such as pyrrolidone carboxylic acid and the like.
  • Whitening agents include ascorbic acid or its derivatives, sulfur, placenta hydrolyzate, ellagic acid or its derivatives, kodiic acid or its derivatives, glucosamine or its derivatives, arbutin or its derivatives, hydroxysilicic acid or its derivatives, glutathione, arnica.
  • Extract Ogon extract, Souhakuhi extract, Psycho extract, Bowfu extract, Mannentake mycelium culture or its extract, Shinanoki extract, Peach leaf extract, Agetsu extract, Kujin extract, Jiyu extract, Touki extract, Yokuinin extract, Kaki leaf extract, Daiou extract , Buttonpi extract, Hamamelis extract, Maronie extract, Otogirisou extract, oil-soluble Kanzo extract and the like.
  • Moisturizers include hyaluronic acid, polyglutamic acid, serine, glycine, threonine, alanine, collagen, hydrolyzed collagen, hydronectin, fibronectin, keratin, elastin, royal jelly, chondroitin sulfate heparin, glycerophospholipid, glyceroglycolipid, sphingolinlipid.
  • Hair restorers include pentadecanoic acid glyceride, Coleus extract, Gentiana extract, Matsukasa extract, Royal jelly extract, Kumazasa extract, t-flabanone, 6-benzylaminopurine, Senburi extract, carpronium chloride, minoxidil, finasteride, adenosine, nicotinic acid amide, Examples thereof include mulberry root extract, dioe extract, and 5-aminolevulinic acid.
  • Extracts and extracts of animals, plants, and crude drugs include Asenyaku (Asenyaku), Ashitaba, Acerola, Artea, Arnica, Avocado, Amacha (sweet tea), Aloe, Aloe vera, Irakusa, Ginkgo (Ginkgo leaf, Ginkgo), and Psyllium (Coptis chinensis).
  • Examples of the microbial culture metabolite include yeast extract, zinc-containing yeast extract, germanium-containing yeast extract, selenium-containing yeast extract, magnesium-containing yeast extract, rice fermented extract, euglena extract, and lactic acid fermented product of defatted milk powder.
  • Examples of ⁇ -hydroxy acids include glycolic acid, citric acid, malic acid, tartaric acid, and lactic acid.
  • Inorganic pigments include silicic anhydride, magnesium silicate, talc, kaolin, bentonite, mica, mica titanium, bismuth oxychloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, calcium carbonate, magnesium carbonate, iron yellow oxide, etc. Examples thereof include red iron oxide, black iron oxide, gunjo, chromium oxide, chromium hydroxide, carbon black, and caramine.
  • Examples of the ultraviolet absorber include p-aminobenzoic acid derivatives, sartylic acid derivatives, anthranyl acid derivatives, coumarin derivatives, amino acid compounds, benzotriazole derivatives, tetrazole derivatives, imidazoline derivatives, pyrimidine derivatives, dioxane derivatives, camphor derivatives and furan derivatives.
  • Examples thereof include pyrone derivatives, nucleic acid derivatives, allantin derivatives, nicotinic acid derivatives, vitamin B6 derivatives, oxybenzones, benzophenones, guaiazulene, ciconin, baikarin, baikarain, and velverine.
  • Astringents include lactic acid, tartaric acid, succinic acid, citric acid, allantin, zinc chloride, zinc sulfate, zinc oxide, calamine, zinc p-phenolsulfonate, potassium aluminum sulfate, resorcin, ferric chloride, tannic acid, etc. Can be mentioned.
  • Antioxidants include ascorbic acid and its salts, stearic acid ester, tocopherol and its ester derivatives, nordihydroguaseletic acid, butylhydroxytoluene (BHT), butylhydroxyanisole (BHA), parahydroxyanisole, propyl gallate. , Sesamol, sesamolin, gosipole, etc.
  • Anti-inflammatory agents include ictamol, indomethacin, kaolin, salicylic acid, sodium salicylate, methyl salicylate, acetylsalicylic acid, diphenhydramine hydrochloride, d or dl-camfur, hydrocortisone, guaiazulene, chamazulene, chlorpheniramine maleate, glycyrrhizinic acid and its salts. Examples thereof include glycyrrhetinic acid and salts thereof.
  • bactericidal / disinfectant examples include acrinol, sulfur, benzalkonium chloride, benzethonium chloride, methylrosaniline chloride, cresol, calcium gluconate, chlorhexidine gluconate, sulfamine, mercurochrome, lactoferrin or a hydrolyzate thereof.
  • selenium disulfide As a hair preparation, selenium disulfide, alkylisoquinolinium bromide solution, zinc pyrithione, biphenamine, thiantoll, castari tincture, ginger tincture, quinine hydrochloride, strong ammonia water, potassium bromate, sodium bromate, thio Glycolic acid and the like can be mentioned.
  • fragrances natural animal fragrances such as jaco, civet, castorium, and amberglis, anis essential oil, angelica essential oil, Iran essential oil, iris essential oil, uikyo essential oil, orange essential oil, cananga essential oil, caraway essential oil, cardamon essential oil, guayakwood essential oil, cumin Essential oil, black letter essential oil, cay skin essential oil, cinnamon essential oil, geranium essential oil, copaiba balsam essential oil, Korean del essential oil, perilla essential oil, cedarwood essential oil, citronella essential oil, jasmine essential oil, gingergrass essential oil, cedar essential oil, spare mint essential oil, western hacker essential oil, large Aroma essential oil, tuberose essential oil, choji essential oil, orange flower essential oil, winter green essential oil, true balsam essential oil, butchery essential oil, rose essential oil, palmarosa essential oil, hinoki essential oil, hiba essential oil, ebony essential oil, petitgrain essential oil, bay essential oil, bechiba essential oil
  • Pigments and colorants include red cabbage pigment, red rice pigment, red rice pigment, annatto pigment, squid ink pigment, corn pigment, enju pigment, okiami pigment, persimmon pigment, caramel, gold, silver, gardenia jasminoides pigment, corn pigment, and onion pigment. , Tamarind pigment, spirulina pigment, buckwheat whole plant pigment, cherry pigment, seaweed pigment, hibiscus pigment, grape juice pigment, marigold pigment, purple potato pigment, purple squid ink pigment, lac pigment, rutin and the like.
  • sweeteners include sugar, sweet tea, fructose, arabinose, galactose, xylose, mannose, maltose, honey, glucose, miraculin, monellin and the like.
  • Examples of the nutritional enhancer include calcined shell calcium, cyanocolabamine, yeast, wheat germ, soybean germ, egg yolk powder, hemicellulose, heme iron and the like.
  • hormones include hormones, metal ion blockers, pH adjusters, chelating agents, preservatives / antibacterial agents, refreshing agents, stabilizers, emulsifiers, animal / vegetable proteins and their decomposition products, animal / vegetable polysaccharides and their derivatives.
  • the dosage form of the present invention is arbitrary, and is in the form of ampoules, capsules, powders, granules, pills, tablets, solids, liquids, gels, bubbles, emulsions, creams, ointments, and sheets. , Mousse-like non-medicinal products, skin / hair cosmetics, bath preparations, foods and drinks, and pharmaceuticals.
  • cosmetics and non-pharmaceutical products include, for example, basic cosmetics such as internal and external medicinal preparations, lotions, emulsions, creams, ointments, lotions, oils, packs, pigments and skin cleansing products, shampoos, etc.
  • basic cosmetics such as internal and external medicinal preparations, lotions, emulsions, creams, ointments, lotions, oils, packs, pigments and skin cleansing products, shampoos, etc.
  • Rinse hair treatment, hair cream, pomade, hair spray, hair styling product, perm agent, hair tonic, hair dye, hair growth / hair growth and other hair cosmetics, foundation, white powder, white powder, lipstick, blusher, eye shadow, eyeliner , Make-up cosmetics such as mascara, eyebrows, eyelashes, finishing cosmetics such as beautiful nails, perfumes, bathing agents, other toothpastes, mouth refreshing agents / mouthwashes, liquid odor / deodorant inhibitors, sanitary products , Sanitary cotton, wet tissue, etc.
  • Foods and drinks include, for example, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks and other beverages, ice cream, ice sherbets, shaved ice and other cold confectionery, buckwheat, udon, shumai, dumpling skin, dumpling skin, and Chinese food.
  • Noodles such as noodles and instant noodles, candy, candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, shumai, confectionery such as bread, crab, salmon, asari, tuna, sardine, shrimp, Marine products such as bonito, mackerel, whale, oyster, saury, squid, red mussel, scallop, abalone, sea urchin, squid, tokobushi, marine and livestock processed foods such as kamaboko, ham, sausage, powdered milk, processed milk, fermented milk, etc.
  • Products, salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, oil and fat processed foods such as dressing, sauces, seasonings such as sauce, curry, stew, parent and child bowl, porridge, miscellaneous dishes, Chinese bowl, and rice bowl , Tendon, Unadon, Hayashi Rice, Oden, Marbodorf, Beef Bowl, Meat Sauce, Egg Soup, Omuraisu, Dumplings, Shumai, Hamburger, Meatballs and other retort pouch foods, various forms of health and nutritional supplements, health functional foods, tablets , Capsules, drinks, troches and the like.
  • composition containing Albizia japonica extract of the present invention is preferably applied to humans, but it can also be applied to animals other than humans as long as the respective effects can be expected.
  • the mode of the cosmetic of the present invention is not particularly limited, but for example, a facial cleanser, a cleaning agent, a lotion (for example, a whitening lotion), a cream (for example, a vanishing cream, a cold cream), a milky lotion, a gel, a beauty liquid, etc.
  • a lotion for example, a whitening lotion
  • a cream for example, a vanishing cream, a cold cream
  • a milky lotion for example, a vanishing cream, a cold cream
  • a milky lotion for example, a vanishing cream, a cold cream
  • a milky lotion for example, a vanishing cream, a cold cream
  • Pack for example, jelly-like peel-off type, paste-like wipe type, powder-like rinse type
  • face mask for example, jelly-like peel-off type, paste-like wipe type, powder-like rinse type
  • face mask for example, cleansing, foundation, lipstick, lip cream, lip gloss, lip liner, cheek red, makeup base, shaving
  • the water extract of Albizia japonica bark used in the following examples was prepared by the method disclosed in JP-A-2018-58783.
  • Example 1 Evaluation of inhibitory or preventive action against disturbance of expression rhythm of target clock gene in human normal neonatal epidermal keratinocytes Using the nemunoki extract as a test sample, the expression rhythm of clock gene was evaluated by the following test method.
  • NHEK Human normal neonatal epidermal keratinocytes
  • Toyobo Collagen Coating Solution
  • HuMedia-KG2 a medium for normal human epidermal keratinocyte proliferation
  • the cells were cultured at 37 ° C. and 10% CO 2 .
  • the medium was changed as appropriate, and the culture was continued until it became 80% or more confluent.
  • trypsin treatment was performed to collect the cells.
  • Cells were seeded on 96-well plates at 1 ⁇ 10 4 cells / well and cultured at 37 ° C. and 10% CO 2 for 1 day.
  • the above-mentioned cultured cells were supplemented with a medium in which dexamethasone was dissolved so as to have a final concentration of 100 nM, incubated for 1 hour, and synchronized stimulation was performed. Then, the medium was removed, the medium was replaced with a medium containing hydrogen peroxide and a test sample at a predetermined concentration, and the mixture was incubated at 37 ° C. and 10% CO 2 for 24 hours.
  • Hydrogen peroxide 0 mM / nemunoki extract 0 mg / mL in the hydrogen peroxide-free group / nemunoki extract-free group hydrogen peroxide 1.5 mM / nemunoki extract in the hydrogen peroxide-added group / nemunoki extract-free group
  • hydrogen peroxide was 1.5 mM / nemunoki extract 50 ⁇ g / mL.
  • cDNA was prepared from the cells using SuperPrep (registered trademark) II Cell Lysis & RT Kit for qPCR (manufactured by Toyobo) after the cells of all levels were collected.
  • the mRNA gene was amplified by qRT-PCR using THUNDERBIRD SYBR (registered trademark) qPCR Mix (manufactured by Toyobo Co., Ltd.).
  • the composition of the reaction solution was in accordance with the package insert. However, the amount of the reaction solution was 20 ⁇ l / well, and the amount of cDNA was 3 ⁇ l.
  • the reaction cycle conditions were 95 ° C., 1 minute ⁇ (95 ° C., 15 seconds ⁇ 60 ° C., 45 seconds) ⁇ 40 ⁇ 95 ° C., 15 seconds ⁇ 60 ° C., 1 minute ⁇ 95 ° C., 15 seconds.
  • the nucleotide sequence shown in SEQ ID NOs: 1 and 2 was used as the primer.
  • the device used was 7500 Fast Real-Time PCR System (Applied Biosystems).
  • the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was used as an internal standard to standardize the expression level of the target gene (SEQ ID NOs: 3-4).
  • the expression level of each standardized target gene was divided by the expression level of the control level gene immediately recovered without adding hydrogen peroxide and the test sample after the completion of the entrainment stimulation, and the relative value was calculated.
  • FIGS. 1 to 3 The obtained results are shown in FIGS. 1 to 3.
  • the expression cycle of Bmal1 was approximately 24 hours, and a normal expression rhythm with a peak at 10 to 11 hours was confirmed.
  • the expression cycle of Bmal1 was 24 hours or more, and an irregular or abnormal expression rhythm with no clear peak was confirmed at 12 to 18 hours.
  • the expression cycle of Bmal1 was about 24 hours, with a peak at 10 to 12 hours, which was close to the normal expression rhythm.
  • the Albizia japonica extract has an effect of suppressing or preventing the expression rhythm of irregular or abnormal clock genes caused by oxidative stress caused by hydrogen peroxide in epidermal cells.
  • Example 2 Formulation of external preparation for skin
  • the following shows a formulation example of the composition containing silk tree extract in the present invention as an external preparation for skin. All of these preparations are expected to have the effect of suppressing or preventing abnormalities in the expression rhythm of clock genes caused by Albizia japonica extract.
  • Toner Toner was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 89.80g ⁇ Glycerin ⁇ ⁇ ⁇ 3.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Pentylene glycol ⁇ ⁇ ⁇ 1.00g ⁇ Albizia extract ⁇ ⁇ ⁇ 1.00g
  • Gel A gel was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 88.50g ⁇ Carbomer ⁇ ⁇ ⁇ 0.30g ⁇ Xanthan gum ⁇ ⁇ ⁇ 0.10g ⁇ Arginine ⁇ ⁇ ⁇ 0.40g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Albizia extract ⁇ ⁇ ⁇ 0.50g
  • Cream A cream was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 58.50g ⁇ Butylene glycol ⁇ ⁇ ⁇ 10.00g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Ethylhexyl glycerin ⁇ ⁇ ⁇ 0.20g ⁇ Squalene ⁇ ⁇ ⁇ 10.00g ⁇ Olive oil ⁇ ⁇ ⁇ 10.00g ⁇ Behenyl alcohol ⁇ ⁇ ⁇ 2.50g -Polyglyceryl pentastearate-10 ... 1.90 g ⁇ Stearoyl lactate Na ⁇ ⁇ ⁇ 0.60g ⁇ Cetyl palmitate ⁇ ⁇ ⁇ 1.00g ⁇ Albizia extract ⁇ ⁇ ⁇ 0.10g
  • Example 3 Erythema suppression test Using the Albizia bark extract as a test sample, an erythema suppression test was carried out by the following test method.
  • Subjects As shown in Table 1, 12 male and female subjects in their 20s and 30s were used as subjects. The average age of the subjects was 33.8 ⁇ 4.9 years (21-39 years).
  • Ultraviolet irradiation uses Multiport SOLAR UV Simulation Model 601 (SOLAR Light Co. Inc., wavelength range: 290 to 400 nm, peak wavelength: 356 nm) as a light source, and its irradiation intensity is a multifunctional measurement system model. Measurements were made using PMA2100 (SOLAR Light Co. Inc.). First, the inside of the upper arm of the subject was irradiated with ultraviolet rays of 0.64, 0.80, 1.00, 1.25, 1.56, 1.95 MED (irradiation for MED determination). Twenty-four hours after irradiation, the MED of each subject was determined (MED determination).
  • each subject was irradiated with ultraviolet rays corresponding to 1.5 MED on the inside of the upper left arm, and four pigmentations having a diameter of about 1 cm were prepared (main irradiation). Skin color measurement was performed 24 hours after the main irradiation.
  • test sample was applied to the inside of the upper arm twice a day in an appropriate amount. The application was carried out for 3 days: the irradiation day for MED judgment, the MED judgment / main irradiation day, and the skin color measurement day.
  • ⁇ a * value a * value (ultraviolet irradiation site) -a * value (non-irradiation site) was calculated. Furthermore, the degree of erythema suppression was evaluated by calculating the ⁇ a * value (after 24 hours) ⁇ a * value (before irradiation) for the test sample coated group and the non-coated group and comparing them.
  • Example 4 Formulation of external composition for skin
  • the following shows a formulation example of the external composition for skin containing the Albizia bark extract of the present invention. All of these preparations are expected to have an erythema-suppressing effect due to the Albizia bark extract, and are effective as anti-inflammatory agents.
  • Toner Toner was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 89.80g ⁇ Glycerin ⁇ ⁇ ⁇ 3.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Pentylene glycol ⁇ ⁇ ⁇ 1.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 1.00g
  • Gel A gel was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 88.50g ⁇ Carbomer ⁇ ⁇ ⁇ 0.30g ⁇ Xanthan gum ⁇ ⁇ ⁇ 0.10g ⁇ Arginine ⁇ ⁇ ⁇ 0.40g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 0.50g
  • Cream A cream was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 58.50g ⁇ Butylene glycol ⁇ ⁇ ⁇ 10.00g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Ethylhexyl glycerin ⁇ ⁇ ⁇ 0.20g ⁇ Squalene ⁇ ⁇ ⁇ 10.00g ⁇ Olive oil ⁇ ⁇ ⁇ 10.00g ⁇ Behenyl alcohol ⁇ ⁇ ⁇ 2.50g -Polyglyceryl pentastearate-10 ... 1.90 g ⁇ Stearoyl lactate Na ⁇ ⁇ ⁇ 0.60g ⁇ Cetyl palmitate ⁇ ⁇ ⁇ 1.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 0.10g
  • Example 5 Glycation suppression test Using the Albizia bark extract as a test sample, a saccharification suppression test was carried out by the following test method.
  • a BSA-glucose mixture was prepared by dissolving 1.6 g of bovine serum albumin (BSA; RIA grade) and 3.0 g of D-glucose in 10 mL of PBS. After filtering the solution with a 0.45 ⁇ m filter, 10% of a 30% butylene glycol (BG) solution in which 1.0% by mass of the test sample (powder) was dissolved was added to the solution at 45 ° C. Incubated for 10 days. As a control addition group, since 30% of BG was contained in the sample, a level was prepared by adding 10% of a 30% BG solution. The mixed sample prepared in the same manner was stored at ⁇ 80 ° C. to prepare a negative control group.
  • BSA bovine serum albumin
  • reaction solution was diluted 10-fold with purified water and 100 ⁇ mL was dispensed into a 96-well microplate.
  • NBD-H 4-Hydrazino-7-nitro-2,1,3-benzoxdiazole Hydrazine
  • trifluoroacetic acid having a final concentration of 0.025%.
  • the amount of carbonyl group in the reaction solution was determined from the calibration curve prepared simultaneously with propionaldehyde.
  • Example 6 Formulation of external composition for skin
  • the following shows a formulation example of the external composition for skin containing the Albizia bark extract of the present invention. All of these preparations are expected to have an anti-glycation effect due to the Albizia bark extract, and are effective as anti-glycation agents.
  • Toner Toner was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 89.80g ⁇ Glycerin ⁇ ⁇ ⁇ 3.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Pentylene glycol ⁇ ⁇ ⁇ 1.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 1.00g
  • Gel A gel was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 88.50g ⁇ Carbomer ⁇ ⁇ ⁇ 0.30g ⁇ Xanthan gum ⁇ ⁇ ⁇ 0.10g ⁇ Arginine ⁇ ⁇ ⁇ 0.40g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Butylene glycol ⁇ ⁇ ⁇ 5.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 0.50g
  • Cream A cream was prepared by a conventional method according to the following composition. ⁇ Purified water ⁇ ⁇ ⁇ 58.50g ⁇ Butylene glycol ⁇ ⁇ ⁇ 10.00g ⁇ Glycerin ⁇ ⁇ ⁇ 5.00g ⁇ Phenoxyethanol ⁇ ⁇ ⁇ 0.20g ⁇ Ethylhexyl glycerin ⁇ ⁇ ⁇ 0.20g ⁇ Squalene ⁇ ⁇ ⁇ 10.00g ⁇ Olive oil ⁇ ⁇ ⁇ 10.00g ⁇ Behenyl alcohol ⁇ ⁇ ⁇ 2.50g -Polyglyceryl pentastearate-10 ... 1.90 g ⁇ Stearoyl lactate Na ⁇ ⁇ ⁇ 0.60g ⁇ Cetyl palmitate ⁇ ⁇ ⁇ 1.00g ⁇ Albizia bark extract ⁇ ⁇ ⁇ 0.10g
  • the expression rhythm of the clock gene is expressed with respect to the skin cells showing the expression rhythm of the clock gene irregularly or abnormally as compared with the expression rhythm of the normal clock gene. It is expected that the abnormalities of the clock gene can be suppressed or prevented, and various diseases and symptoms caused by the disorder of the expression rhythm of the clock gene can be prevented. Further, by using an anti-inflammatory agent or a composition for external use on the skin containing the nemunoki bark extract of the present invention, it is possible to suppress erythema induced by ultraviolet rays and the like, and it is expected to be used as an anti-inflammatory agent. To.
  • the anti-glycation agent and the external composition for skin containing the nemunoki bark extract of the present invention it is possible to effectively suppress the production of glycation products generated by the reaction between protein and sugar, and anti-glycation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne : une composition pour supprimer ou prévenir des perturbations du rythme d'expression du gène-horloge; une composition pour prévenir l'érythème de la peau induite par la lumière ultraviolette et similaire ; et une composition pour empêcher la génération de produits glyqués par la réaction d'une protéine et d'un sucre.　La présente invention concerne une composition pour supprimer ou prévenir des perturbations du rythme d'expression du gène-horloge, un agent anti-inflammatoire et un agent anti-glycation qui contiennent un extrait d'Albizia julibrissin.
PCT/JP2020/022683 2019-07-05 2020-06-09 Composition contenant un extrait d'albizia julibrissin WO2021005941A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202080035514.4A CN113825493A (zh) 2019-07-05 2020-06-09 含有合欢提取物的组合物
JP2021530534A JPWO2021005941A1 (fr) 2019-07-05 2020-06-09

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2019-126007 2019-07-05
JP2019126007 2019-07-05
JP2019202195 2019-11-07
JP2019-202195 2019-11-07
JP2019-204511 2019-11-12
JP2019204511 2019-11-12

Publications (1)

Publication Number Publication Date
WO2021005941A1 true WO2021005941A1 (fr) 2021-01-14

Family

ID=74114182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/022683 WO2021005941A1 (fr) 2019-07-05 2020-06-09 Composition contenant un extrait d'albizia julibrissin

Country Status (3)

Country Link
JP (1) JPWO2021005941A1 (fr)
CN (1) CN113825493A (fr)
WO (1) WO2021005941A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022202241A1 (fr) * 2021-03-25 2022-09-29 東洋紡株式会社 Inhibiteur de dommage à l'adn induit par uv

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114470050B (zh) * 2022-03-21 2023-09-05 上海相宜本草化妆品股份有限公司 一种抗敏、舒缓、止痒和/或修复皮肤的中药复方组合物
CN115282098B (zh) * 2022-08-26 2023-03-21 珠海市丝域生物科技有限公司 一种具有抑菌和去屑功效的组合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010235548A (ja) * 2009-03-31 2010-10-21 Maruzen Pharmaceut Co Ltd 抗酸化剤、抗炎症剤、美白剤、抗老化剤、育毛剤、及び抗肥満剤、並びに化粧料、及び飲食品
JP2015509072A (ja) * 2011-09-27 2015-03-26 セダーマ ネムノキ抽出物の新規な美容的使用およびそれに応じた局所組成物
US20160008268A1 (en) * 2014-07-11 2016-01-14 Mary Kay Inc. Pore minimizer
CN106473999A (zh) * 2016-12-27 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种抗非酶糖基化衰老化妆品组合物及其制备方法
JP2018058783A (ja) * 2016-10-04 2018-04-12 コンビ株式会社 時計遺伝子の発現を変化させるための組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010235548A (ja) * 2009-03-31 2010-10-21 Maruzen Pharmaceut Co Ltd 抗酸化剤、抗炎症剤、美白剤、抗老化剤、育毛剤、及び抗肥満剤、並びに化粧料、及び飲食品
JP2015509072A (ja) * 2011-09-27 2015-03-26 セダーマ ネムノキ抽出物の新規な美容的使用およびそれに応じた局所組成物
US20160008268A1 (en) * 2014-07-11 2016-01-14 Mary Kay Inc. Pore minimizer
JP2018058783A (ja) * 2016-10-04 2018-04-12 コンビ株式会社 時計遺伝子の発現を変化させるための組成物
CN106473999A (zh) * 2016-12-27 2017-03-08 广州赛莱拉干细胞科技股份有限公司 一种抗非酶糖基化衰老化妆品组合物及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022202241A1 (fr) * 2021-03-25 2022-09-29 東洋紡株式会社 Inhibiteur de dommage à l'adn induit par uv

Also Published As

Publication number Publication date
CN113825493A (zh) 2021-12-21
JPWO2021005941A1 (fr) 2021-01-14

Similar Documents

Publication Publication Date Title
JP3966922B2 (ja) 線維芽細胞増殖促進剤
JP4205188B2 (ja) メイラード反応阻害剤
JP3914244B2 (ja) 異常タンパク質除去用組成物
JP5018171B2 (ja) 植物由来の賦活化剤及び細胞外マトリックス産生促進剤
WO2011036786A1 (fr) Agent de relâchement du stress comprenant un extrait contenant une polyamine dérivée d'une plante comme ingrédient actif
JP3966924B2 (ja) 植物抽出物含有線維芽細胞増殖促進剤
WO2021005941A1 (fr) Composition contenant un extrait d'albizia julibrissin
KR20110131498A (ko) 패각 또는 패산호로부터 추출한 알카리용액에 은이온을 포함하는 항균제와 이를 포함하여 조성된 조성물.
JP2002241293A (ja) メイラード反応阻害剤
JPWO2007148737A1 (ja) 植物抽出物の調製方法、並びに植物抽出物及びその用途
JP2003212770A (ja) メイラード反応阻害剤
WO2019159588A1 (fr) Agent anti-pollution et composition topique pour la peau
JP2003095913A (ja) 化粧料組成物又は飲食品
KR102113193B1 (ko) 청호, 병풀 및 녹차의 혼합 추출물 또는 이의 분획물을 유효 성분으로 함유하는 피부 상태 개선용 조성물 및 이를 이용한 피부 상태 개선 방법
JP4104180B2 (ja) リパーゼ活性促進剤
JP2023171681A (ja) 抗酸化剤
JP7428426B2 (ja) コラーゲン産生促進剤
JP2002138044A (ja) 前駆脂肪細胞分化誘導阻害剤
JP2013166785A (ja) 植物由来ストレス軽減剤
JP2009292756A (ja) ポリアミン含有ストレス軽減剤
JP6831549B2 (ja) Ａｂｃａ１２遺伝子発現促進剤
JP2021075495A (ja) 抗炎症剤
JP4169814B2 (ja) リュウゼツラン又はサイザル抽出物含有皮膚外用剤
JP5578160B2 (ja) 植物由来の賦活化剤及び細胞外マトリックス産生促進剤
JP2003119151A (ja) 化粧料組成物又は飲食品

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20836485

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021530534

Country of ref document: JP

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20836485

Country of ref document: EP

Kind code of ref document: A1